Overview

NK Cells in Cord Blood Transplantation

Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies. Giving chemotherapy with or without total body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
American Cancer Society, Inc.
Celgene
National Cancer Institute (NCI)
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Immunoglobulins
Lenalidomide
Mechlorethamine
Melphalan
Mycophenolate mofetil
Mycophenolic Acid
Nitrogen Mustard Compounds
Rituximab
Tacrolimus
Vidarabine